RS 0337
Alternative Names: RS-0337Latest Information Update: 18 Jan 2023
At a glance
- Originator RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
- Developer PDC Therapeutics; RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
- Class Antineoplastics; Drug conjugates; Polymers
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer; Gastric cancer
Most Recent Events
- 02 Jan 2023 RS 0337 is available for licensing as of 02 Jan 2023. https://pdcbio.com/about-us/
- 02 Jan 2023 Preclinical trials in Breast cancer in Turkey (unspecified route) (RS Research pipeline, January 2023)
- 02 Jan 2023 Preclinical trials in Gastric cancer in Turkey (unspecified route) (RS Research pipeline, January 2023)